8 recruiting, 3 not yet recruiting, 1 active not recruiting, 1 withdrawn. 13 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 8, Not yet recruiting 3, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 7 | Recruiting 3, Not yet recruiting 2, Active not recruiting 1, Withdrawn 1 |
Follow Lupus Nephritis (LN): new trials by email Literature Review of Lupus Nephritis (LN) trials Research Report on Lupus Nephritis (LN)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy C-CAR168 - Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE) | Phase 2 | Not yet recruiting | AbelZeta Inc. | 50 | 2026-09-30 | 2026-10-13 |
| Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis TranspoCART19 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Recruiting | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 10 | 2026-09-23 | 2026-10-01 |
| A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | iCell Gene Therapeutics | 20 | 2026-09-01 | 2026-09-17 |
| A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G ADX-097 - IgA Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Akebia Therapeutics | 30 | 2026-07-30 | 2026-10-01 |
| C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease C-CAR168 - Lupus Nephritis (LN) | Phase 1 / Phase 2 | Withdrawn | AbelZeta Inc. | 2026-07-01 | 2026-07-16 | |
| Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis Dapagliflozin (10Mg Tab) along with standard medical therapy, Proteinuria Quantification - Lupus Nephritis (LN), Chronic Kidney Disease | Phase 1 / Phase 2 | Active not recruiting | Hospital Civil Juan I. Menchaca | 30 | 2026-05-28 | 2026-07-01 |
| Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus CRC01 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Not yet recruiting | Curocell Inc. | 39 | 2026-02-01 | 2026-01-23 |
| The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment Glucocorticoids, belimumab, Telitacicept - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | Nanjing University School of Medicine | 50 | 2025-12-08 | 2026-03-12 |
| Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN HSK39297 200mgQD, HSK39297 300mgQD, Placebo - Lupus Nephritis (LN) | Phase 2 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 105 | 2025-11-18 | 2026-01-23 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis HLX79 10mg/kg/Placebo+HLX01, HLX79 20mg/kg/Placebo + HLX01, HLX79 30mg/kg/placebo+HLX01 - Membranous Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Shanghai Henlius Biotech | 24 | 2025-08-05 | 2025-11-18 |
| MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease. Injection of MSC303 - Lupus Nephritis (LN), ANCA-Associated Glomerulonephritis | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Changzheng Hospital | 12 | 2025-06-20 | 2025-06-11 |
| CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus CART19 - SLE, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 24 | 2025-05-06 | 2026-09-24 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus CD19 CAR-T cells - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 18 | 2024-10-17 | 2026-03-10 |
Lupus Nephritis (13) · Lupus Erythematosus, Systemic (9) · Autoimmune Diseases (3) · Complement Component 3 Deficiency, Autosomal Recessive (1) · Disease (1) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranous (1) · Renal Insufficiency, Chronic (1)
Connective Tissue Diseases (13) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Glomerulonephritis (13) · Immune System Diseases (13) · Kidney Diseases (13) · Male Urogenital Diseases (13) · Nephritis (13) · Skin and Connective Tissue Diseases (13) · Urogenital Diseases (13) · Urologic Diseases (13) · Autoimmune Diseases (10) · Lupus Erythematosus, Systemic (4) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Adrenal Cortex Hormones (1) · CTL019 chimeric antigen receptor (1) · Glucocorticoids (1) · Mycophenolic Acid (1) · Tablets (1) · belimumab (1) · dapagliflozin (1) · telitacicept (1)
AbelZeta Inc. (2) · Akebia Therapeutics (1) · Beijing GoBroad Hospital (1) · Children's Hospital of Philadelphia (1) · Curocell Inc. (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Hospital Civil Juan I. Menchaca (1) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1) · Nanjing University School of Medicine (1) · Shanghai Changzheng Hospital (1) · Shanghai Henlius Biotech (1) · iCell Gene Therapeutics (1)
China (5) · United States (4) · Brazil (1) · Mexico (1) · Spain (1)
Alberto Ortiz Arduan (1) · Caitlin Elgarten, MD (1) · Huji Xu, Ph.D, MD (1) · Scott Antonia (1) · Scott Antonia, MD, PhD (1)
2025 (1)